PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Tirzepatide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptors, given once weekly. · pmid:34186022

History

In SURMOUNT-1, 2,539 adults with obesity lost 15.0% to 20.9% of body weight over 72 weeks across three doses, against 3.1% on placebo. · pmid:35658024

In SURPASS-1, every dose was superior to placebo over 40 weeks for HbA1c, fasting glucose and body weight in type 2 diabetes managed by diet and exercise alone. · pmid:34186022

Identity

PubChem CID 166567236: CID 166567236, C225H348N48O68, 4813 g/mol. · pubchem:166567236

CAS registry number 2023788-19-2. · pubchem:166567236

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Tirzepatide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. (2021) · establishedTirzepatide Once Weekly for the Treatment of Obesity. (2022) · established20212022

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Tirzepatide yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. · pmid 34186022 · 2021
    • Tirzepatide Once Weekly for the Treatment of Obesity. · pmid 35658024 · 2022
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.